Cvrx, INC Form 4 insider transactions

Brent Binkowski, CHIEF OPERATING OFFICER of CVRx, Inc., purchased 26,223 shares of common stock on August 13, 2026 for $2.91 per share.

Brent Binkowski, CHIEF OPERATING OFFICER of CVRx, Inc., sold 1,309 shares of common stock on August 12, 2026 for $2.55 per share.

Director Kirk G. Nielsen acquired 8,720 shares of common stock and 11,182 stock options as part of an annual equity grant.

Director Mudit K. Jain acquired 8,720 shares of common stock and 11,182 stock options as part of an annual equity grant.

Director Joseph P. Slattery acquired 8,720 shares of common stock and 11,182 stock options in CVRx, Inc.

Director Mitch C. Hill acquired 8,720 shares of common stock and 11,182 stock options as part of an annual equity grant.

Director Kevin J. Ballinger acquired 8,720 shares of common stock and 11,182 stock options in CVRx, Inc. as part of an equity compensation grant.

Director Martha Shadan was granted 8,720 shares of common stock and 11,182 stock options in CVRx, Inc.

Director Michael Dale acquired 29,005 shares of common stock and 36,252 stock options in CVRx, Inc. as part of an annual grant.

CVRx's Chief Medical Officer, Philip B. Adamson, reported significant equity acquisitions through restricted stock units and stock options, alongside a routine sale of common stock to satisfy tax withholding obligations.

CVRx, Inc.'s Chief Human Resources Officer, Gregory Morrison, was granted 34,000 restricted stock units and 154,500 stock options on March 2, 2026.

CVRx, Inc.'s President and CEO, Kevin Hykes, reported the acquisition of 159,000 restricted stock units and 238,000 stock options, alongside a tax-related sale of 7,763 shares.

CVRx's Chief Marketing & Strategy Officer, Paul Verrastro, acquired new equity awards and sold shares to cover tax withholding obligations.

CVRx Chief Financial Officer Jared Oasheim acquired 61,000 restricted stock units and 91,000 stock options, while selling 1,744 shares to cover tax obligations.

CVRx's Chief Revenue Officer, John Robert Allen, acquired 35,000 restricted stock units and 52,000 stock options, while selling 3,964 shares to cover tax obligations.

CVRx, Inc. Chief Operating Officer Brent Binkowski was granted 15,000 restricted stock units and 23,000 stock options as part of his compensation.

CVRx Director Mudit K. Jain purchased 46,800 shares of common stock, increasing his indirect beneficial ownership in the company.

Johnson & Johnson's subsidiary, JJDC, amended its Form 4 filing to disclose additional sales of CVRx, Inc. common stock totaling 22,337 shares in late 2025.

Johnson & Johnson, through its subsidiary, disposed of 6,337 shares of CVRx, Inc. common stock at a weighted average price of $10.03 per share.

Johnson & Johnson, through its subsidiary, reported the sale of 2,700 shares of CVRx, Inc. common stock in two transactions.

Johnson & Johnson, through its subsidiary JJDC, Inc., reported the sale of 1,000 shares of CVRx, Inc. common stock at a weighted average price of $10.00 per share.

Johnson & Johnson's subsidiary, JJDC, reported the sale of 52,532 shares of CVRx, Inc. common stock in early November 2025.

CVRx, Inc.'s Chief Operating Officer, Brent Binkowski, was granted 16,600 restricted stock units and 74,900 stock options, aligning his compensation with long-term company performance.

CVRx, Inc. Director Kirk G. Nielsen has acquired 19,554 stock options with an exercise price of $6.76, which are set to vest by June 2026.

CVRx, Inc. Director Mudit K. Jain was granted 19,554 stock options with an exercise price of $6.76, vesting by June 2026, aligning his interests with shareholder value.

CVRx, Inc. Director Joseph P. Slattery was granted 19,554 stock options with an exercise price of $6.76, aligning his interests with long-term shareholder value.

CVRx, Inc. Director Mitch Hill was granted 19,554 stock options with an exercise price of $6.76, vesting by June 2026 and expiring in June 2035.

CVRx, Inc. Director Kevin J. Ballinger was granted 19,554 stock options with an exercise price of $6.76, vesting by June 2026.

CVRx, Inc. Director Martha Shadan reported the acquisition of 19,554 stock options with an exercise price of $6.76, vesting by June 2026.

Director Kirk G. Nielsen reports purchasing 10,966 shares of CVRx, Inc. at an average price of $5.4528 on May 15, 2025.